{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:45:54Z","timestamp":1785181554373,"version":"3.55.0"},"reference-count":56,"publisher":"Radcliffe Medical Media Ltd","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Cardio-oncology is a recently developed field in cardiology aimed at significantly reducing cardiovascular morbidity and mortality and improving quality of life in cancer survivors. Cancer survival rates have been constantly increasing, mainly because of the advent of new, more potent and targeted therapies. However, many of the new therapies \u2013 along with some of the older chemotherapeutic regimens such as anthracyclines \u2013 are potentially cardiotoxic, which is reflected increasingly frequently in the published literature. Cardiotoxicity adversely affects prognosis in cancer patients, thus its prevention and treatment are crucial to improve quality and standards of care. This review aims to explore the existing literature relating to chemotherapy- and radiotherapy-induced cardiotoxicity. An overview of the imaging modalities for the identification of cardiotoxicity and therapies for its prevention and management is also provided.<\/jats:p>","DOI":"10.15420\/ecr.2017:17:2","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T16:01:32Z","timestamp":1535040092000},"page":"64","source":"Crossref","is-referenced-by-count":96,"title":["Cardio-oncology: A Focus on Cardiotoxicity"],"prefix":"10.15420","volume":"13","author":[{"given":"Athanasios","family":"Koutsoukis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens Alexandra Hospital, Athens, Greece","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyrios","family":"Ntalianis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens Alexandra Hospital, Athens, Greece","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Repasos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens Alexandra Hospital, Athens, Greece","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efsthathios","family":"Kastritis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens Alexandra Hospital, Athens, Greece","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens Alexandra Hospital, Athens, Greece","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Paraskevaidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens Alexandra Hospital, Athens, Greece","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","unstructured":"1. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.","journal-title":"Ann Intern Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","unstructured":"2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.","journal-title":"Eur J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy","volume":"53","author":"ET","year":"2009","unstructured":"3. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy. J Am Coll Cardiol 2009;53:2231-47.","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/imj.13201","article-title":"Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis","volume":"46","author":"Clark","year":"2016","unstructured":"4. Clark RA, Berry NM, Chowdhury MH, et al. Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis. Intern Med J 2016;46:1297-306.","journal-title":"Intern Med J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11739-011-0744-y","article-title":"Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology","volume":"7","author":"Raschi","year":"2012","unstructured":"5. Raschi E, De Ponti F. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med 2012;7:113-31.","journal-title":"Intern Emerg Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","unstructured":"6. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016;133:1104-14.","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","unstructured":"7. Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016;37:2768-01.","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"MS","year":"2015","unstructured":"8. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015;12:547-58.","journal-title":"Nat Rev Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ijcard.2013.03.133","article-title":"Cardioncology: state of the heart","volume":"168","author":"Todaro","year":"2013","unstructured":"9. Todaro MC, Oreto L, Qamar R, et al. Cardioncology: state of the heart. Int J Cardiol 2013;168:680-7.","journal-title":"Int J Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","unstructured":"10. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134:75-82.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: what the cardiologist needs to know","volume":"7","author":"MS","year":"2010","unstructured":"11. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010;7:564-75.","journal-title":"Nat Rev Cardiol"},{"key":"ref11","unstructured":"12. Herrmann J, Yang EH ,Iliescu CA, et al. Vascular toxicities of cancer therapies the old and the new - an evolving avenue."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","unstructured":"13. Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv 2017;1:1739-48.","journal-title":"Blood Adv"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Setteyova L, Bacharova L, Mladosievicova B. QT prolongation due to targeted anticancer therapy. Oncoreview 2016;6:A103-112.","DOI":"10.5604\/20828691.1220896"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy","volume":"70","author":"Chang","year":"2017","unstructured":"15. Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2017;70:2536-51.","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","unstructured":"16. Montani D, Bergot E, G\u00fcnther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128-37.","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1186\/1471-2407-14-915","article-title":"Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring","volume":"14","author":"Chari","year":"2014","unstructured":"17. Chari A, Hajje D. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer. 2014;14:915.","journal-title":"BMC Cancer"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000333016","article-title":"Reversible pulmonary hypertension related to thalidomide treatment for multiple myeloma","volume":"4","author":"Villa","year":"2011","unstructured":"18. Villa A, Mazzola AA, Ghio S, et al. Reversible pulmonary hypertension related to thalidomide treatment for multiple myeloma. Case Rep Oncol. 2011;4(3):487-9.","journal-title":"Case Rep Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1161\/CIRCULATIONAHA.115.018351","article-title":"Cardiovascular complications of novel multiple myeloma treatments","volume":"133","author":"Li","year":"2016","unstructured":"19. Li W, Cornell RF, Lenihan D, et al. Cardiovascular complications of novel multiple myeloma treatments. Circulation 2016;133:908-12.","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","unstructured":"20. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012;119:933-9.","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/heartjnl-2015-308765","article-title":"Radiation-induced valvular heart disease","volume":"102","author":"Gujral","year":"2016","unstructured":"21. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart 2016;102:269-76.","journal-title":"Heart"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1253\/jcj.63.803","article-title":"Cardiac disease late after chest radiotherapy for Hodgkin's disease","volume":"63","author":"Toyofuku","year":"1999","unstructured":"22. Toyofuku M, Okimoto T, Tadehara F, et al. Cardiac disease late after chest radiotherapy for Hodgkin's disease. Jpn Circ J 1999;63:803-5.","journal-title":"Jpn Circ J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.7326\/0003-4819-124-5-199603010-00019","article-title":"Delayed appearance of effusive-constrictive pericarditis after radiation for Hodgkin lymphoma","volume":"124","author":"Kane","year":"1996","unstructured":"23. Kane GC, Edie RN, Mannion JD. Delayed appearance of effusive-constrictive pericarditis after radiation for Hodgkin lymphoma. Ann Intern Med 1996;124:534-5.","journal-title":"Ann Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","unstructured":"24. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-8.","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7326\/0003-4819-125-1-199607010-00008","article-title":"Anthracycline-induced cardiotoxicity","volume":"125","author":"Shan","year":"1996","unstructured":"25. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.","journal-title":"Ann Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamacardio.2016.2132","article-title":"Oncocardiology - past, present, and future","volume":"1","author":"ET","year":"2016","unstructured":"26. Yeh ET, Chang HM. Oncocardiology - past, present, and future. JAMA Cardiol 2016;1:1066-72.","journal-title":"JAMA Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 2012:23(Suppl 7): vii155-66.","DOI":"10.1093\/annonc\/mds293"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Fukuda A, Tahara K, Hane Y, et al. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS One 2017;12:e0185654.","DOI":"10.1371\/journal.pone.0185654"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","unstructured":"29. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 2016;375:1457-67.","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","unstructured":"30. Eschenhagen T, Force T, Ewer M, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13:1-10.","journal-title":"Eur J Heart Fail"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Pond\u00e9 NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 2016;1:e000073.","DOI":"10.1136\/esmoopen-2016-000073"},{"issue":"6","key":"ref31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","article-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies","volume":"113","author":"Ky","year":"2013","unstructured":"32. Ky B, Vejpongsa P, Yeh ETH, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res. 2013;113(6):754-64.","journal-title":"Circ Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","unstructured":"33. Ghatalia P, Morgan CJ, Je Y, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2015;94:228-37.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","article-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies","volume":"113","author":"Ky","year":"2013","unstructured":"34. Ky B, Vejpongsa P, Yeh ET, et al. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 2013;113:754-64.","journal-title":"Circ Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","article-title":"Cardiovascular complications of proteasome inhibitors used in multiple myeloma","volume":"26","author":"DC","year":"2018","unstructured":"35. Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Cardiol Rev 2018;26:122-9","journal-title":"Cardiol Rev"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ijc.1295","article-title":"Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience","volume":"93","author":"Gollerkeri","year":"2001","unstructured":"36. Gollerkeri A, Harrold L, Rose M, et al. Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience. Int J Cancer 2001;93:139-41.","journal-title":"Int J Cancer"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","unstructured":"37. Johnson D, Balko J, Compton M, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749-55.","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Bloom MW, Hamo CE, Cardinale D, et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 1: Definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail 2016;9:e002661.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","unstructured":"39. van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015;175:1007-17.","journal-title":"JAMA Intern Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.radonc.2013.08.009","article-title":"Radiation-induced carotid artery atherosclerosis","volume":"110","author":"Gujral","year":"2014","unstructured":"40. Gujral DM, Chahal N, Senior R, et al. Radiation-induced carotid artery atherosclerosis. Radiother Oncol 2014;110:31-8.","journal-title":"Radiother Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","unstructured":"41. Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc 2014;89:1287-306.","journal-title":"Mayo Clin Proc"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pcad.2010.04.002","article-title":"Role of biomarkers in chemotherapy-induced cardiotoxicity","volume":"53","author":"Cardinale","year":"2010","unstructured":"42. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010;53:121-29.","journal-title":"Prog Cardiovasc Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert Consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"10","author":"Plana","year":"2014","unstructured":"43. Plana JC, Galderisi M, Barac A, et al. Expert Consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;10:1063-93.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/0002-8703(83)90080-7","article-title":"Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance","volume":"106","author":"Choi","year":"1983","unstructured":"44. Choi BW, Berger HJ, Schwartz PE, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 1983;106:638-43.","journal-title":"Am Heart J"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1532-429X-15-48","article-title":"Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling","volume":"15","author":"Tham","year":"2013","unstructured":"45. Tham EB, Haykowsky MJ, Chow K, et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Resonan 2013;15:48.","journal-title":"J Cardiovasc Magn Resonan"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46. Hamo CE, Bloom MW, Cardinale D, et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 2: Prevention, treatment, guidelines, and future directions. Circ Heart Fail 2016;9:e002843.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002843"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and bio- markers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","unstructured":"47. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and bio- markers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596-603.","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","unstructured":"48. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684-92.","journal-title":"Br J Cancer"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.mayocp.2016.06.029","article-title":"Cancer history portends worse acute and Long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction","volume":"91","author":"Wang","year":"2016","unstructured":"49. Wang F, Gulati R, Lennon R, et al. Cancer history portends worse acute and Long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Mayo Clin Proc 2016;91:1680-1692.","journal-title":"Mayo Clin Proc"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50. Iliescu CA, Grines CL, Herrmann J, et al. SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv 2016;87:E202-23.","DOI":"10.1002\/ccd.26375"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): A randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","unstructured":"51. Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): A randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 2017;35:870-7.","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","unstructured":"52. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-81.","journal-title":"Circulation"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","unstructured":"53. Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016;37:1671-80.","journal-title":"Eur Heart J"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: A randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","unstructured":"54. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: A randomized clinical trial. JAMA Oncol 2016;2:1030-7.","journal-title":"JAMA Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study","volume":"60","author":"Seicean","year":"2012","unstructured":"55. Seicean S, Seicean A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012;60:2384-90.","journal-title":"J Am Coll Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11897-017-0353-9","article-title":"Prevention of chemotherapy induced cardiomyopathy","volume":"14","author":"DL","year":"2017","unstructured":"56. Payne DL, Nohria A. Prevention of chemotherapy induced cardiomyopathy. Curr Heart Fail Rep 2017;14:398-403.","journal-title":"Curr Heart Fail Rep"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articles\/cardio-oncology-focus-cardiotoxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T15:38:01Z","timestamp":1599579481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articles\/cardio-oncology-focus-cardiotoxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"alternative-id":["ecr.2017:17:2"],"URL":"https:\/\/doi.org\/10.15420\/ecr.2017:17:2","relation":{},"ISSN":["1758-3756"],"issn-type":[{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}